Possible Localization of Compounds in the Prostate: Distribution of Diphenylphosphoramido-Phenylphosphoric Acid

Publisher Website
Google Scholar
Abstract
The presence in high concentration of phosphatase in the prostate suggested experiments on the possible localization of diphenylphosphoramidophenyl-phosphoric acid (IMP). The compound labeled with P32 was prepared. Its excretion was determined in drugs. Urinary excretion of radioactivity was initially rapid and much greater than by the biliary route. Tissue radioactivity at varying periods after administration was greatest in liver, kidney, lung, skin and prostate in order of decreasing concentration. Administration of diphenyl N-(4-hydroxyphenyl) phos-phoramidate (D3P) labeled with P32 to dogs caused a distribution of tissue radioactivity similar to that observed with the D4P. When D4P was given to humans suffering with metastatic carcinoma of the prostate, it was rapidly excreted in the urine, at first probably as unchanged D4P, later as metabolites. In 2 cases out of 9 P32 in the prostate was in significant excess of that in serum. The radioactivity of adjacent tissues was usually less than that in the prostatic. Autopsy specimens of liver, kidney and lung contained a large amount of P32. The data present no conclusive evidence that the action of prostatic phosphatase had more than a transient effect in the tissue localization of the radioactive ester of phosphoric acid which was given.